Financial Performance - The company's revenue for Q1 2023 reached ¥11,172,773,125.45, representing a 26.37% increase compared to ¥8,841,150,250.19 in the same period last year[4] - Net profit attributable to shareholders was ¥2,032,024,553.16, a 5.68% increase from ¥1,922,756,886.80 year-on-year[4] - Basic earnings per share for Q1 2023 was ¥1.2700, reflecting a 5.68% increase from ¥1.2017 in the same quarter last year[4] - Total operating revenue for Q1 2023 reached CNY 11,172,773,125.45, a significant increase from CNY 8,841,150,250.19 in Q1 2022, representing a growth of approximately 26.9%[19] - Net profit for Q1 2023 was CNY 2,032,024,553.16, compared to CNY 1,922,756,886.80 in the same period last year, reflecting an increase of about 5.7%[20] - The company reported a total comprehensive income of CNY 2,032,024,553.16 for Q1 2023, compared to CNY 1,922,756,886.80 in the same period last year, showing an increase of about 5.7%[21] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, with a net outflow of ¥1,040,028,831.23, a 68.64% reduction from the previous year's outflow of ¥3,316,743,954.40[11] - The company reported a significant increase in cash and cash equivalents of ¥176,160,972.80, a 107.60% improvement compared to a significant decrease in the previous year[11] - The cash inflow from financing activities totaled 2,866,915,531.74 CNY, an increase from 1,720,866,416.95 CNY in the prior period[24] - The net cash flow from financing activities was 1,491,721,904.16 CNY, compared to 1,412,329,711.67 CNY in the previous period[24] - The cash and cash equivalents at the end of the period amounted to 2,791,849,824.14 CNY, up from 1,961,452,199.09 CNY in the prior period[24] - The company experienced a net increase in cash and cash equivalents of 176,160,972.80 CNY, contrasting with a decrease of -2,318,248,546.21 CNY in the previous period[24] Assets and Liabilities - Total assets increased by 13.78% to ¥43,242,428,755.31 from ¥38,003,733,941.95 at the end of the previous year[5] - The total assets of the company increased to CNY 43,242,428,755.31 from CNY 38,003,733,941.95 at the beginning of the year, marking a growth of about 13.5%[18] - Total current liabilities increased to CNY 16.36 billion from CNY 13.23 billion, which is an increase of approximately 23.8%[17] - The company's total liabilities reached CNY 16.97 billion, compared to CNY 13.77 billion at the beginning of the year, indicating a growth of approximately 23.9%[17] Research and Development - The company's R&D expenses rose to ¥213,960,021.59, marking a 32.98% increase compared to ¥160,890,893.91 in the prior year[10] - Research and development expenses amounted to CNY 213,960,021.59, up from CNY 160,890,893.91 in Q1 2022, indicating a year-over-year increase of approximately 33%[20] Equity and Shareholder Information - The total equity attributable to shareholders increased by 8.38% to ¥26,268,237,162.33 from ¥24,236,212,609.17 at the end of the previous year[5] - The company's total equity attributable to shareholders reached CNY 26,268,237,162.33, up from CNY 24,236,212,609.17 at the beginning of the year, indicating a growth of approximately 8.4%[18] Employee Compensation and Engagement - The company reported a significant increase in employee compensation liabilities, which decreased to CNY 36.53 million from CNY 182.21 million, indicating a reduction of approximately 80%[17] - The company is actively involved in employee stock ownership plans, with specific funds allocated for this purpose, indicating a strategic focus on employee engagement and retention[14] Other Financial Metrics - The weighted average return on equity decreased to 8.05%, down by 2.28% from 10.33% in the same period last year[4] - Tax expenses for Q1 2023 were CNY 360,264,719.19, slightly higher than CNY 340,224,600.65 in Q1 2022, reflecting an increase of approximately 5.9%[20] - The total operating costs for Q1 2023 were CNY 8,596,876,197.85, up from CNY 6,503,327,142.16 in the same period last year, reflecting an increase of about 32.4%[19] Audit Status - The first quarter report was not audited[25]

Financial Performance - In 2022, the company's revenue exceeded 38.2 billion CNY, and net profit surpassed 7.5 billion CNY, demonstrating significant growth in performance[2]. - Chongqing Zhifei Biological Products Co., Ltd. reported a total revenue of RMB 3.5 billion in 2022, representing a year-on-year increase of 15%[18]. - The company achieved a net profit of RMB 1.2 billion, with a profit margin of approximately 34%[18]. - The company's operating revenue for 2022 was approximately ¥38.26 billion, representing a 24.83% increase from ¥30.65 billion in 2021[22]. - The net profit attributable to shareholders for 2022 was approximately ¥7.54 billion, a decrease of 26.15% compared to ¥10.21 billion in 2021[22]. - The net cash flow from operating activities for 2022 was approximately ¥1.99 billion, down 76.62% from ¥8.51 billion in 2021[22]. - The total assets at the end of 2022 were approximately ¥38.00 billion, an increase of 26.48% from ¥30.05 billion at the end of 2021[22]. - The company's basic earnings per share for 2022 were ¥4.71, down 26.15% from ¥6.38 in 2021[22]. - The company reported a net profit of approximately ¥29.10 million from non-recurring gains and losses in 2022, compared to ¥24.41 million in 2021[27]. - The company reported a sound financial condition with a well-established financial system and accurate financial reports reflecting the 2022 operating results[141]. Research and Development - The company has established three major R&D bases in Beijing, Anhui, and Chongqing, with nine R&D technology platforms and eight product matrices, showcasing its comprehensive capability from R&D to industrialization[2]. - The company has successfully launched seven self-developed products, including the world's first approved recombinant COVID-19 protein vaccine, highlighting its innovation strength[2]. - The company aims to enhance its R&D capabilities by focusing on independent research and development, with plans to launch important products like PCV15 and MCV4 vaccines[7]. - The company has established a clinical research team of over 100 members to enhance the speed of clinical research projects, aiming for timely product launches to benefit the public[10]. - The company has 28 projects in its research pipeline, with 16 projects already in the registration process, enhancing its core competitiveness[42]. - The company is actively involved in the development of mRNA technology through its investment in a biotechnology platform[34]. - The company is advancing multiple vaccine research projects, including a broad-spectrum COVID-19 vaccine based on mRNA technology[57]. - The company has obtained a total of 42 patents to date, indicating a strong focus on intellectual property management[45]. - The company has launched the second-generation COVID-19 vaccine (Omicron-Delta chimeric vaccine) international clinical trial in Uzbekistan[57]. Market Expansion and Strategy - The global human vaccine market is projected to grow from approximately 27.7 billion USD in 2017 to about 46 billion USD in 2021, with expectations to reach around 131 billion USD by 2030[4]. - The Chinese vaccine market is expected to exceed 340 billion CNY by 2030, driven by increasing health awareness and government policies supporting the pharmaceutical industry[4]. - The company plans to expand its market presence by launching three new vaccine products in 2023, targeting both domestic and international markets[18]. - The company aims to achieve a revenue growth target of 10% for 2023, driven by new product launches and market expansion strategies[18]. - The company is focusing on international team building to improve overseas registration, product certification, and commercial promotion capabilities, leveraging successful experiences from its COVID-19 vaccine WHO-EUL certification[10]. - The company is committed to contributing to the Healthy China strategy and supporting national development goals through its growth and innovation efforts[10]. - The company is actively pursuing international partnerships and product registration to enhance vaccine accessibility and equity[64]. Quality and Compliance - The company has a production qualification rate of 100% and has received EU QP certification and WHO-EUL verification for its COVID-19 vaccine, indicating high-quality standards[4]. - The company emphasizes compliance with national regulations in the production and distribution of vaccines, ensuring quality management throughout the production process[39]. - The company maintains a 100% pass rate for product batch release since 2008, ensuring high-quality standards[52]. - The company is committed to optimizing the management of early-stage research, clinical studies, and drug registration processes to expedite the launch of high-quality products[10]. - The company targets a 100% qualification rate for product quality management, adhering strictly to laws and industry standards[96]. Corporate Governance and Management - The company has established a comprehensive quality management system covering all stages from R&D to sales[52]. - The company adheres to strict governance structures, with a board of directors comprising 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[108]. - The company has a clear policy for remuneration that aligns with its operational performance and strategic goals[128]. - The company has a structured compensation decision-making process based on profitability and individual performance[128]. - The company has established a talent management strategy to cultivate a skilled workforce in the biopharmaceutical sector, focusing on fair and diverse recruitment policies[99]. - The company has a well-defined governance structure, including independent shareholder meetings and boards[113]. - The company has not faced any penalties from securities regulatory agencies in the past three years[127]. Environmental Responsibility - The company adheres to environmental protection laws and regulations, fulfilling its ecological responsibilities[164]. - The company has implemented a green and sustainable development strategy in its operations[164]. - The company has established pollution discharge standards, including a limit of 0.6 mg/L for total phosphorus, which is part of the compliance measures[172]. - The company has implemented a comprehensive pollution monitoring system, ensuring compliance with environmental regulations and standards[177]. - The company has established an emergency response plan for environmental incidents and conducts regular drills to enhance response capabilities[176]. - The company achieved 100% compliance in waste disposal, preventing environmental pollution[175]. Employee Engagement and Culture - The company has implemented a comprehensive employee training system focusing on cultural, professional, and leadership training[147]. - The company emphasizes a performance-based compensation system to motivate employees and align their interests with the company's growth[145]. - The company has established an employee stock ownership plan involving 1,923 core employees, with a total of 29,100,000 shares held, accounting for 1.82% of the total share capital[154]. - The company has a total of 1,210 production staff, 3,359 sales personnel, and 807 technical staff, reflecting a diverse professional composition[144]. - The workforce increased by 935 employees, a growth rate of 19.48%, bringing the total to 5,735 employees[53].

证券代码：300122 证券简称：智飞生物 公告编号：2023-15 重庆智飞生物制品股份有限公司 关于举行2022年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2023 年 3 月 21 日 1 重庆智飞生物制品股份有限公司（以下简称"公司"）《2022年年度报告》 已于2023年3月21日公布于中国证监会指定信息披露网站巨潮资讯网。为进一步 解读公司年度报告，帮助广大投资者更深入全面地了解公司经营情况，公司定于 2023年4月6日（星期四）15:00-17:00在全景网举行2022年度业绩网上说明会。 本次年度业绩说明会将采用网络远程的方式举行，投资者可登陆"全景路演" （http://rs.p5w.net）参与会议，与公司管理层互动、沟通。 出席本次年度业绩说明会的人员情况如下：董事长兼总裁蒋仁生先生、董 事会秘书秦菲先生、财务总监李振敬先生、独立董事袁林女士。 为充分尊重投资者，广泛听取投资者的意见和建议，现就公司2022年度业绩 说明会提前向投资者公开征集问题，提问通道自发出公告之日起开放。投资者可 于2023年4月6日（ ...

Group 1: Event Details - Chongqing Zhifei Biological Products Co., Ltd. will participate in the 2022 Investor Online Collective Reception Day on December 23, 2022 [1] - The event will take place from 15:00 to 17:00, and the login address for the platform is http://rs.p5w.net [1] Group 2: Purpose and Goals - The event aims to enhance corporate governance and improve the quality of listed companies in the Chongqing area [1] - It is organized under the guidance of the Chongqing Securities Regulatory Bureau and in collaboration with the Chongqing Listed Companies Association, Shanghai Stock Exchange Information Network Co., Ltd., and Shenzhen Qianjing Network Co., Ltd. [1] Group 3: Participation and Communication - Senior management of the company will engage in online communication regarding governance, development strategy, and operational status [1] - The company expresses gratitude to investors for their support and encourages active participation [1]

Group 1: Industry Impact and Regulations - The Shandong vaccine incident has a long-term positive impact on the vaccine industry, leading to market consolidation towards compliant companies [3] - The company adheres strictly to GMP and GSP standards, ensuring no business dealings with unqualified entities [3] - Future regulations on vaccine management are expected to become stricter, affecting procurement, cold chain, and distribution processes [4] Group 2: HPV Vaccine Development - The HPV vaccine has shown good application globally, with ongoing technical reviews and administrative approvals [4] - The company has a contract with MSD for the HPV vaccine, which includes a 3-year sales period and a potential 2-year extension upon task completion [4] - The company is currently the sole provider of the AC-Hib combination vaccine, with no immediate competition expected for at least 3 years [4] Group 3: Safety and Efficacy of Domestic Vaccines - Domestic vaccines have demonstrated safety, with only 9 adverse reactions reported from over 100 million doses of measles vaccine in 2010 [5] - The quality of domestic vaccines is approaching or exceeding EU standards, with some indicators even surpassing foreign products [5] - The vaccine industry is expected to undergo a transformation, with a reduction in the number of manufacturers as the market consolidates [4] Group 4: Market Dynamics and Future Strategies - The company anticipates that the vaccine market will not be dominated by a large number of producers, but will gradually concentrate [4] - The recent vaccine incident has prompted the health authorities to strengthen circulation and vaccination management, which may lead to centralized procurement [6] - The company is focusing on early-stage investments in biopharmaceuticals, particularly in oncology, cardiovascular, and metabolic areas [6]

Financial Performance - In the first half of 2021, the company achieved a revenue of 13.171 billion yuan, representing an increase of 88.33% compared to the same period last year [1] - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was 1.055 billion yuan, reflecting a growth of 263.73% year-on-year [1] Product Development and Market Strategy - The company collaborated with the Institute of Microbiology, Chinese Academy of Sciences, to develop the ZhiKeWei vaccine, which received emergency use approval in March 2021 [2] - The company is actively expanding its international business, with successful exports of its products to Indonesia, Pakistan, and Uzbekistan [2] - The company’s tuberculosis product matrix includes two approved products, enhancing its "diagnosis, prevention, and treatment" system for tuberculosis [3] Research and Development Investment - In the first half of 2021, the company invested 790 million yuan in research and development, supporting various ongoing projects [3] - The company plans to utilize up to 3 billion yuan of its own funds for cash management and potential acquisitions in technology platforms [3] Sales and Marketing - The company’s marketing team has grown to over 2,500 members, which supports effective execution of marketing strategies and operational plans [4] - The sales expense ratio remained stable compared to the previous year, attributed to product launch timing and market team development [4] Regulatory and Compliance - The company is focused on complying with national vaccination plans and is monitoring the effectiveness of its products against variant strains of the virus [2] - The company is committed to transparency in disclosing performance and regulatory compliance, particularly regarding its partnership with Merck for HPV vaccines [4]

Financial Performance - In the first three quarters of 2021, the company achieved an operating income of 21.829 billion CNY, representing a year-on-year growth of 97.55% [1] - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was 8.418 billion CNY, an increase of 239.06% compared to the same period last year [1] Product Development and Market Expansion - The company has actively promoted its products, including the COVID-19 vaccine, which has been approved for emergency use and is contributing to domestic epidemic prevention efforts while also being exported to international markets [2] - The company is focusing on the development of new vaccines and has obtained key data from Phase III clinical trials for its recombinant COVID-19 vaccine, demonstrating good safety and efficacy [2] Strategic Initiatives - The company is committed to a "technology + market" dual-driven development model, increasing R&D investment and advancing various projects [2] - The company is also preparing for the international certification of its products and aims to expand its global business footprint [2] HPV Vaccine Market Response - The company is monitoring the introduction of domestic HPV vaccines and is prepared to respond to market changes, ensuring a diverse range of vaccination options for the public [3] - As of mid-2021, the company has issued over 30 million doses of HPV vaccines, covering more than 10 million individuals [3] Tuberculosis Product Development - The company has launched two tuberculosis products, forming a comprehensive system for the diagnosis, prevention, and treatment of tuberculosis [4] - The newly approved product for preventing latent tuberculosis infections is the first of its kind in the market [4] R&D Pipeline Progress - The company has 26 projects in its R&D pipeline, with 16 projects entering the registration process [4] - Significant progress has been made in various vaccine projects, including the completion of clinical trials for several vaccines [4]

Revenue and Profit - Revenue for Q3 2022 reached ¥9,469,539,012.34, an increase of 9.38% year-over-year, while year-to-date revenue was ¥27,823,286,821.00, up 27.46% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2022 was ¥1,878,137,901.60, a decrease of 35.52% year-over-year, with year-to-date net profit at ¥5,607,155,253.07, down 33.28%[3] - Basic earnings per share for Q3 2022 was ¥1.1738, reflecting a decline of 35.53% compared to the same period last year[3] - The company's net profit for the third quarter of 2022 was CNY 5,607,155,253.07, compared to CNY 8,403,607,789.29 in the same quarter of the previous year, reflecting a decrease of approximately 33.5%[21] - The net profit attributable to the parent company for Q3 2022 was CNY 5,607,155,253.07, a decrease of 33.7% from CNY 8,403,607,789.29 in the same period last year[22] - The company’s total comprehensive income for Q3 2022 was CNY 5,607,155,253.07, reflecting a decline of 33.7% from CNY 8,403,607,789.29 in the previous year[22] Assets and Liabilities - Total assets as of the end of Q3 2022 amounted to ¥36,227,856,518.53, representing a 20.57% increase from the end of the previous year[4] - The total liabilities as of September 30, 2022, were CNY 13,923,488,353.63, compared to CNY 12,390,110,553.53 at the beginning of the year, representing an increase of approximately 12.4%[20] - The total equity attributable to shareholders rose to ¥22,304,368,164.90, a 26.32% increase from the previous year[4] - The total equity attributable to shareholders of the parent company reached CNY 22,304,368,164.90, up from CNY 17,657,212,911.83 at the beginning of the year, indicating an increase of about 26.9%[20] Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net amount of ¥989,225,797.01, down 88.11% year-to-date[3] - The net cash flow from operating activities was ¥989,225,797.01, an 88.11% decrease from ¥8,321,407,156.74 in the previous period, mainly due to increased payments for goods[11] - The net cash flow from financing activities was -¥1,453,367,548.21, a 62.14% improvement from -¥3,838,489,899.06 in the previous period, primarily due to an increase in short-term borrowings received[11] - Cash inflow from operating activities for the period was CNY 22,468,907,315.97, an increase of 19.0% compared to CNY 18,778,634,686.71 in the previous year[23] - Cash outflow from operating activities totaled CNY 21,479,681,518.96, up from CNY 10,457,227,529.97, indicating a significant increase in operational expenses[23] - The net cash flow from financing activities was -CNY 1,453,367,548.21, an improvement from -CNY 3,838,489,899.06 in the same period last year[24] - The ending cash and cash equivalents balance was CNY 2,663,776,410.21, down from CNY 4,244,270,666.85, indicating a decrease in liquidity[24] Research and Development - Research and development expenses for Q3 2022 increased by 152.77% to ¥607,498,775.07, indicating a strong focus on innovation[9] - Research and development expenses increased significantly to CNY 607,498,775.07 from CNY 240,340,975.29 year-on-year, marking an increase of about 152.5%[21] Inventory and Receivables - Accounts receivable increased by 46.87% to ¥18,898,354,770.39, primarily due to higher sales revenue[8] - Inventory as of September 30, 2022, was CNY 8,067,216,185.86, up from CNY 7,385,396,274.99 at the beginning of the year, indicating an increase of about 9.2%[19] Borrowings and Financing - The company reported a significant increase in short-term borrowings, which rose by 228.24% to ¥1,867,200,500.65, reflecting increased financing needs[8] - The company's short-term borrowings rose significantly to CNY 1,867,200,500.65 from CNY 568,858,956.43, representing an increase of approximately 228.5%[19] Vaccine Production - The company issued 2.69 million units of ACYW135 polysaccharide vaccine and 4.36 million units of AC conjugate vaccine during the reporting period, indicating ongoing commitment to the vaccine market[16] - The four-valent HPV vaccine saw a significant increase in issuance, with 11.81 million units issued, representing a 158% year-on-year growth[16] - The nine-valent HPV vaccine issuance reached 12.28 million units, reflecting a 128% year-on-year increase[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 92,353, with the largest shareholder holding 48.32% of the shares[12] - The company's cash and cash equivalents decreased to ¥2,672,454,279.80 from ¥4,307,751,548.35 at the beginning of the year, indicating a significant reduction in liquidity[17]